US jobs and R&D spending are on the line if US drug pricing reform measures pass paving the way for the government to directly negotiate Medicare drug prices with manufacturers, big pharma leaders warned during an industry-sponsored press briefing on 8 September.
Pharma On Its Back Foot As US Drug Price Reform Advances
Big pharma leaders warn of steep cuts to R&D and US jobs if US drug pricing reform legislation paves the way for direct government price negotiations.
